Hodgkin lymphoma trials in Germany

In Germany 17 Also abroad 155

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Berlin, Cologne, Magdeburg
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1/2Taking people
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Where
Essen, Giessen, Munich, Wuerzburg
Age
18 years and over
People
280 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Muenster
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Cologne, Essen, Frankfurt Am Main
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Berlin, Chemnitz, Essen, Jena, Wuerzburg
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Berlin, Cologne, Erlangen, Würzburg
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 2Taking people
PREFer
Where
Aachen, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Chemnitz, Cologne, Darmstadt, Dresden, Erlangen, Essen, Esslingen am Neckar, Flensburg, Frankfurt Am Main, Fulda, Giessen, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kempten (Allgau), Leipzig, Luebeck, Luedenscheid, Moenchengladbach, Munich, Offenburg, Paderborn, Regensburg, Rostock, Siegen, Stade, Stuttgart, Trier, Ulm, Villingen-Schwenningen, Wuerzburg
Age
18 years and over
People
50
Run by
University Of Cologne
See details and how to joinNCT06916416 · EU 2024-520138-31-00
Phase 1/2Taking people
QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers
Where
Berlin, Dresden, Erlangen, Essen, Hamburg, Marburg, Munich, Ulm
Age
18 years and over
People
60
Run by
Avencell Therapeutics Inc.
See details and how to join2025-521735-36-00 · EU 2025-521735-36-00
Phase 1/2Taking people
A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
Where
Freiburg im Breisgau, Mainz
Age
18 years and over
People
30 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2025-524915-36-00 · EU 2025-524915-36-00
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Muenster, Tuebingen
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 3Taking people
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Where
Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
Age
61 years and over
People
330 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00
Phase 3Taking people
A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
Where
Frankfurt (Oder)
Age
18 years and over
People
132 worldwide
Run by
Regeneron Pharmaceuticals Inc.
See details and how to joinNCT06230224 · EU 2022-502783-21-00
Phase 1/2Taking people
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Where
Frankfurt am Main, Stuttgart
Age
18 years and over
People
23 worldwide
Run by
BioInvent International AB
See details and how to joinNCT03571568 · EU 2024-512972-36-00
Phase 2Taking people
Pembro-FLASH
Where
Berlin, Bremen, Chemnitz, Cologne, Essen, Frankfurt Am Main, Goettingen, Hamburg, Munich, Stuttgart
Age
18 years to 64 years
People
40
Run by
University Of Cologne
See details and how to joinNCT06045159 · EU 2022-501458-13-01
Phase 2Not yet taking people in Germany
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Where
Berlin, Bremen, Cologne, Essen, Hamburg, Heidelberg, Munich
Age
18 years to 60 years
People
35
Run by
University of Cologne
See details and how to joinNCT06919679 · EU 2025-521749-26-00
Phase 2Not yet taking people in Germany
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
Where
Cologne
Age
18 years to 60 years
People
40
Run by
University of Cologne
See details and how to joinNCT06045195
Phase 1/2Taking people
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Where
Heidelberg
Age
3 years and over
People
68
Run by
University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00